Altimmune, Inc. (ALT) vs 908 Devices Inc. (MASS)
A side-by-side comparison of Altimmune, Inc. and 908 Devices Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ALT
Altimmune, Inc.
$2.67HealthcareDelayed quote: Oct 6, 2026, 10:35 AM EDT
MASS
908 Devices Inc.
$12.53HealthcareDelayed quote: Oct 6, 2026, 10:35 AM EDT
Total return — ALT vs MASS
growth of $100 · dividends reinvested · last 6yALT -79.3% (-23.1%/yr)MASS -73.9% (-20.0%/yr)MASS compounded faster over this window
ALT MASS
ALT vs MASS: by the numbers
- •ALT is the larger company ($519M vs $514M market cap).
- •Both run net losses; MASS's is the smaller (-56.68% vs -296000.00% net margin).
- •MASS grew revenue faster over the past five years (18.92% vs -65.38% CAGR).
Metrics side by side
Valuation
| Metric | ALT | MASS |
|---|---|---|
| P/S ratio | 16730.41 | 8.45 |
| P/B ratio | 1.09 | 4.06 |
| FCF yield | N/A | 0.09% |
Profitability
| Metric | ALT | MASS |
|---|---|---|
| Gross margin | 100.00% | 49.79% |
| Operating margin | -230460.98% | -46.01% |
| Net margin | -296000.00% | -56.68% |
| ROE | -19.35% | -27.20% |
| ROIC | -19.47% | -18.90% |
Growth (annualized)
| Metric | ALT | MASS |
|---|---|---|
| Revenue CAGR (5Y) | -65.38% | 18.92% |
| Total return CAGR (5Y) | -25.30% | -17.66% |
Frequently asked
- Which has grown faster, ALT or MASS?
- Over the past five years, MASS grew revenue faster — ALT at a -65.38% CAGR versus MASS at 18.92%.
- How have ALT and MASS total returns compared?
- Over the past 5 years, ALT delivered -25.30% and MASS delivered -17.66% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Altimmune ROE908 Devices ROEAltimmune operating margin908 Devices operating marginAltimmune revenue growth908 Devices revenue growthAltimmune free cash flow908 Devices free cash flow
Altimmune & 908 Devices appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.